scholarly journals Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis

2017 ◽  
Vol Volume 9 ◽  
pp. 251-260 ◽  
Author(s):  
Jack Burks ◽  
Thomas Marshall ◽  
Xiaolan Ye
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Disease Modifying Therapies ◽  
Disease Modifying

scholarly journals The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)

2020 ◽  
Author(s):  
Nils-Henning Ness ◽  
Rocco Haase ◽  
Raimar Kern ◽  
Dirk Schriefer ◽  
Benjamin Ettle ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Discriminant Validity ◽  
Response Rate ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Retest Reliability ◽  
Study Results ◽  
Patient Reported ◽  
Test Retest Reliability

BACKGROUND Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. OBJECTIVE The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. METHODS We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. RESULTS In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (<i>r</i>=0.411, <i>P</i>&lt;.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. CONCLUSIONS The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.

scholarly journals The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

10.2196/17921 ◽  
2020 ◽  
Vol 22 (3) ◽  
pp. e17921 ◽  
Author(s):  
Nils-Henning Ness ◽  
Rocco Haase ◽  
Raimar Kern ◽  
Dirk Schriefer ◽  
Benjamin Ettle ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Discriminant Validity ◽  
Response Rate ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Retest Reliability ◽  
Study Results ◽  
Patient Reported ◽  
Test Retest Reliability

Background Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. Objective The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. Methods We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. Results In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. Conclusions The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.

Der Multiple Sclerosis Health Resource Utilization Survey

2021 ◽  
Author(s):  
Nils-Henning Ness ◽  
Dirk Schriefer ◽  
Rocco Haase ◽  
Tjalf Ziemssen
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Indirekte Kosten

Zusammenfassung Hintergrund In gesundheitsökonomischen Studien sind valide und verlässliche Kostendaten essentiell, um belastbare Schlussfolgerungen zu ziehen und eine höchstmögliche Versorgungsqualität der Patienten sicherzustellen. Im Falle der Multiplen Sklerose (MS) basieren solche Studien häufig auf Primärdaten, deren zugrundeliegende Erhebungsinstrumente nicht publiziert sind. Zudem erschweren heterogene Methoden die Vergleichbarkeit und Interpretation solcher Studienergebnisse. Zur Vereinheitlichung gesundheitsökonomischer Studien in der MS wurde der Multiple Sclerosis Health Resource Utilization Survey (MS-HRS) entwickelt, validiert und frei zugänglich publiziert. Fragestellung Fokus dieser Übersichtsarbeit bildet der MS-HRS. Wir berichten methodische Grundlagen zur Krankheitskostenerfassung sowie MS-HRS basierte Ergebnisse zu den Kosten der Krankheitsdynamik bei Personen mit MS. Material/Methodik Dieser Artikel beruht auf einer selektiven Literaturrecherche zum MS-HRS und zu den gesundheitsökonomischen Aspekten der Krankheitskostenerfassung. Ergebnisse Der MS-HRS erfasst patientenberichtet die gesellschaftliche Inanspruchnahme von direkten medizinischen, direkten nicht-medizinischen sowie indirekten Ressourcen. Indirekte Kosten werden weiterhin zwischen Absentismus, sowohl kurzzeitig (Krankheitstage) als auch langfristig (Erwerbs-/Berufsunfähigkeit), und Präsentismus unterschieden. Der Ressourcenverbrauch wird mit den gesellschaftlichen Opportunitätskosten approximiert. Erste MS-HRS basierte Analysen zeigen, dass neben dem stationären Behinderungsgrad und dem klinischen Verlauf auch die Krankheitsdynamik in Form von Schüben und Progression enorme sozioökonomische Auswirkungen hat. Diskussion Valide Krankheitskostendaten bringen Transparenz in die ökonomischen Auswirkungen von Erkrankungen. In Ergänzung zu klinischen Daten kann die Kosteneffektivität festgestellt werden und somit Anhaltspunkte für eine effizientere Patientenversorgung aufgedeckt werden. Im Falle der MS steht zur Kostenerfassung ein frei zugängliches Instrument (MS-HRS) zur Verfügung.

Sign in / Sign up

Export Citation Format

Share Document